Highlights PharmaTher Holdings Ltd.

Equities

PHRM

CA71716H1082

Market Closed - Canadian Securities Exchange Other stock markets 03:59:14 2024-04-29 pm EDT			5-day change	1st Jan Change
0.25 ^CAD	+4.17%		+16.28%	-20.63%

Apr. 23	PharmaTher Holdings Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended February 29, 2024	CI
Apr. 16	PharmaTher Updated on its Priority Original Abbreviated New Drug Application for Ketamine	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

PharmaTher Holdings Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended February 29, 2024	Apr. 22	CI
PharmaTher Updated on its Priority Original Abbreviated New Drug Application for Ketamine	Apr. 16	MT
PharmaTher Holdings Ltd. Provides Update of Its Priority Original Abbreviated New Drug Application for Ketamine	Apr. 16	CI
PharmaTher Provides Update on its Priority Original Abbreviated New Drug Application For Ketamine	Feb. 12	MT
PharmaTher Holdings Ltd. Provides Update of Its Priority Original Abbreviated New Drug Application for Ketamine	Feb. 12	CI
PharmaTher Holdings Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2023	Jan. 26	CI
PharmaTher Provided Update for Expected FDA Approval of Ketamine	Jan. 10	MT
PharmaTher Holdings Ltd. Provides an Update for Its Lead Drug, Ketamine	Jan. 10	CI
PharmaTher Holdings Ltd. Reports Earnings Results for the First Quarter Ended August 31, 2023	23-10-30	CI
PharmaTher Holdings Ltd. Reports Earnings Results for the Full Year Ended May 31, 2023	23-09-28	CI
PharmaTher Announced FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for Ketarx	23-09-27	MT
PharmaTher Brief: Notes FDA assigns GDUFA goal date of April 29, 2024	23-09-27	MT
PharmaTher Brief: Announcing FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX (Ketamine)	23-09-27	MT
PharmaTher Holdings Ltd. Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX(TM)	23-09-27	CI
PharmaTher Submits Priority Original Abbreviated New Drug Application for Ketarx (Ketamine) to FDA	23-09-06	MT
PharmaTher Brief: Submitting Priority Original Abbreviated New Drug Application for KETARX (Ketamine) to FDA	23-09-06	MT
PharmaTher Holdings Ltd. Submits Priority Original Abbreviated New Drug Application for KETARX? to the FDA	23-09-06	CI
PharmaTher Reports "Positive" Research Results for PharmaPatch with DMT and Strategic Investment into Sairiyo Therapeutics	23-07-18	MT
PharmaTher Brief: Announcing "Positive" Research Results for PharmaPatch with N,N-dimethyltryptamine (DMT) and Strategic Investment into Sairiyo Therapeutics	23-07-18	MT
PharmaTher Holdings Ltd. Announces Positive Research Results for PharmaPatch with N,N-Dymethyltryptamine and Strategic Investment into Sairiyo Therapeutics	23-07-18	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights PharmaTher Holdings Ltd.

Equities

PHRM

CA71716H1082

Highlights

Filters